Trials / Recruiting
RecruitingNCT06082102
Efficacy and Safety of Orelabrutinib Combined With Rituximab Versus Lenalidomide Combined With Rituximab in Patients With Relapsed/Refractory Marginal Zone Lymphoma
A Randomized, Controlled, Open-label, Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of Orelabrutinib Plus Rituximab Versus Lenalidomide Plus Rituximab in Relapsed/Refractory Marginal Zone Lymphoma
- Status
- Recruiting
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 324 (estimated)
- Sponsor
- Beijing InnoCare Pharma Tech Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Efficacy and Safety of Orelabrutinib Combined with Rituximab versus Lenalidomide Combined with Rituximab in Patients with Relapsed/Refractory Marginal Zone Lymphoma
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Orelabrutinib | Orelabrutinib Tablets |
| DRUG | Rituximab | Rituximab Injection |
| DRUG | Lenalidomide | Lenalidomide Capsules |
| DRUG | Rituximab | Rituximab Injection |
Timeline
- Start date
- 2023-12-19
- Primary completion
- 2028-08-31
- Completion
- 2030-02-25
- First posted
- 2023-10-13
- Last updated
- 2025-09-15
Locations
19 sites across 1 country: China
Source: ClinicalTrials.gov record NCT06082102. Inclusion in this directory is not an endorsement.